GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
After market 18:56:45 | |||
| 68.49 USD | +8.46% |
|
68.1 | -0.57% |
| 06-20 | Equity Markets Close Mixed as Investors Weigh Economic Data | MT |
| 06-20 | Equity Markets Close Mixed After Macro Data | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.49
USD
Average target price
82.7
USD
Spread / Average Target
+20.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.45% | 85.33B | |
| +51.99% | 798B | |
| -5.72% | 356B | |
| +18.94% | 328B | |
| +11.07% | 304B | |
| +16.96% | 244B | |
| +2.25% | 227B | |
| +11.15% | 216B | |
| +7.59% | 166B | |
| -3.65% | 157B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies
